amit@unlistedkraft.in
+91-9599071664
+91-9599071664
Sigachi Laboratories Limited Unlisted Shares
DRHP Status : Not Filed
50
Fundamentals About Sigachi Laboratories Limited
Downloads & Investor Documents
All documents are provided for informational purposes and are subject to regulatory disclosures.
Key Financials of Sigachi Laboratories Limited
| P&L Statement | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | 260 | 195 | 374 | 312 |
| Cost of Material Consumed | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 |
| Gross Margins | 100 | 100 | 100 | 100 |
| Employee Benefit Expenses | 34 | 36 | 39 | 43 |
| Other Expenses | 15 | 17 | 93 | 160 |
| EBITDA | 211 | 142 | 242 | 109 |
| OPM | 81.15 | 72.82 | 64.71 | 34.94 |
| Other Income | 44 | 50 | 62 | 66 |
| Finance Cost | 0 | 0 | 0 | 0 |
| D&A | 17 | 19 | 23 | 23 |
| EBIT | 194 | 123 | 219 | 86 |
| EBIT Margins | 74.62 | 63.08 | 58.56 | 27.56 |
| PBT | 238 | 173 | 281 | 152 |
| PBT Margins | 91.54 | 88.72 | 75.13 | 48.72 |
| Tax | 38 | 42 | 84 | 33 |
| PAT | 200 | 131 | 197 | 119 |
| NPM | 76.92 | 67.18 | 52.67 | 38.14 |
| EPS | 2.74 | 1.79 | 2.69 | 1.63 |
Financial Ratios |
2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Operating Profit Margin | 81.15 | 72.82 | 64.71 | 34.94 |
| Net Profit Margin | 76.92 | 67.18 | 52.67 | 38.14 |
| Earning Per Share (Diluted) | 2.74 | 1.79 | 2.69 | 1.63 |
| Assets | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Fixed Assets | 229 | 237 | 321 | 310 |
| CWIP | 0 | 0 | 0 | 0 |
| Investments | 2151 | 1966 | 2663 | 2978 |
| Trade Receivables | 16 | 1 | 20 | 3 |
| Inventory | 0 | 0 | 0 | 0 |
| Other Assets | 632 | 922 | 730 | 800 |
| Total Assets | 3028 | 3126 | 3734 | 4091 |
| Liabilities | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Share Capital | 731 | 731 | 731 | 731 |
| FV | 10 | 10 | 10 | 10 |
| Reserves | 2244 | 2343 | 2870 | 3202 |
| Borrowings | 0 | 0 | 0 | 0 |
| Trade Payables | 0 | 0 | 0 | 0 |
| Other Liabilities | 53 | 52 | 133 | 158 |
| Total Liabilities | 3028 | 3126 | 3734 | 4091 |
About Company
Sigachi Laboratories Limited, incorporated in 1994 and based in Telangana, India, is an active public company primarily engaged in manufacturing bulk drugs and drug intermediates. While traditionally a pharmaceutical manufacturer, the company has recently derived significant revenue from lease rentals and investments in equity and mutual funds. It is listed on the Metropolitan Stock Exchange of India.
The following table shows a 10-point analysis of Sigachi Laboratories Limited. We will discuss each point in detail after this table.
| Parameter | Key Numbers | Insights |
|---|---|---|
| Business Overview | Incorporated 1994 | Public company engaged in pharma/chemical-related activities. |
| Industry | Pharmaceuticals & Chemicals | Operates in the medicinal and chemical products segment. |
| Core Activities | Manufacturing · financial/lease income | Mixed income model with operational + financial activities. |
| Business Model | Hybrid | Earnings from operations, interest income, and lease rentals. |
| Revenue | ₹3.74 Cr (FY24) | Strong YoY growth from FY23 |
| Profitability | ₹1.97 Cr PAT (FY24) | Healthy profitability improvement |
| Balance Sheet | Net worth growth | Strengthened reserves and asset base |
| Debt Position | Low leverage | Conservative financial structure |
| Scale | Small-cap operations | Limited scale compared to industry peers |
| Outlook | Stable but niche | Growth linked to income streams diversification |
Company Overview
(i) Sigachi Laboratories Limited is a public limited company incorporated in 1994, engaged in pharmaceutical, chemical, and related business activities.
(ii) The company operates with a hybrid business model, deriving income from manufacturing activities as well as financial sources such as interest income and lease rentals.
(iii) Over the years, Sigachi Laboratories has maintained a lean operational structure, focusing on efficient capital utilization and steady income generation.
(iv) The company has also deployed capital in inter-corporate deposits and financial assets, contributing to its earnings stability.
(v) Its overall performance is influenced by both operational activity and financial income streams, making it slightly different from traditional pharma manufacturing companies.
Challenges in Sigachi Laboratories Limited’s Business
- Small scale of operations: Limited revenue base restricts scalability and market positioning.
- Dependence on non-operational income: A significant portion of income comes from financial activities rather than core operations.
- Volatility in earnings: Quarterly performance shows fluctuations in revenue and profitability.
- Limited growth visibility: Absence of large-scale expansion plans may restrict long-term growth potential.
Financial Review of Sigachi Laboratories Limited
Here are some highlights of the financial performance of Sigachi Laboratories Limited over the past few years.
FY24 Performance
• Revenue from operations stood at ₹3.74 crore
• Profit before tax stood at ₹2.81 crore
• Profit after tax reported at ₹1.97 crore
• Strong growth with 92% revenue increase YoY
FY23 Performance
• Revenue from operations stood at ₹1.95 crore
• Profit before tax stood at ₹1.73 crore
• Profit after tax reported at ₹1.31 crore
• Moderate growth with stable profitability
FY22 Performance
• Total income stood at ₹3.04 crore (approx.)
• Profitability remained positive
• Net worth showed steady growth
• Stable financial position maintained
Quick Summary
Sigachi Laboratories Limited is a small-scale pharma and financial hybrid business with consistent profitability and improving financial performance in recent years. However, its limited scale, dependence on non-operational income, and earnings volatility remain key considerations for investors.
Click here to visit the official website of Sigachi Laboratories Limited.
Promoters of Sigachi Laboratories Limited
The following are the active promoters/leadership associated with the company:
| Name | Designation |
|---|---|
| China Sai Babu Puppala | Director |
| Rajasekhar Tunuguntla | Whole-time Director |
| Shilpa Bung | Director |
Shareholding Pattern of Sigachi Laboratories Limited
| Name | Holding |
|---|---|
| Promoters | 36.86% |
| Resident Individual | 49.59% |
| NRI | 20.48% |
| Other | 2.07% |
Promoters of Sigachi Laboratories Limited
| Name | Designation | Experience | Linkedin Profile |
|---|---|---|---|
| Sri. T. Adinarayana | Chairman | 30+ |  |
| Sri. T.R. Sekhar | Executive Director | 25+ | |
| Mr. B. Kumar | CFO | 25+ | |
Latest News
Latest Post
Coming soon...
Coming soon...
Frequently Asked Questions
Sigachi Laboratories Limited unlisted shares are equity shares of the company that are not listed on NSE or BSE and are traded privately.
Yes, Sigachi Laboratories Limited unlisted shares can be purchased through private market platforms, subject to availability.
Yes, a demat account is required to hold Sigachi Laboratories Limited unlisted shares.
Sigachi Laboratories Limited has shown consistent profitability but operates at a small scale with volatile income streams, making it a moderate-risk unlisted investment.
Yes, Sigachi Laboratories Limited unlisted shares can be sold in the secondary market depending on buyer availability.
Yes, as per SEBI regulations, pre-IPO investors are subject to a six-month lock-in period after listing.
If held for more than two years, gains are taxed at 20% with indexation; otherwise taxed as per income slab.
+91-9599071664
amit@unlistedkraft.in